First Trust Advisors LP Sells 237,317 Shares of Johnson & Johnson (JNJ)

First Trust Advisors LP decreased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 54.6% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 197,341 shares of the company’s stock after selling 237,317 shares during the period. First Trust Advisors LP’s holdings in Johnson & Johnson were worth $23,945,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the business. BlackRock Inc. grew its stake in shares of Johnson & Johnson by 4.7% in the 1st quarter. BlackRock Inc. now owns 175,389,024 shares of the company’s stock worth $22,476,102,000 after purchasing an additional 7,853,141 shares during the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of Johnson & Johnson by 1.8% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 30,303,272 shares of the company’s stock worth $3,676,999,000 after purchasing an additional 541,338 shares during the last quarter. Fisher Asset Management LLC grew its stake in shares of Johnson & Johnson by 3.8% in the 2nd quarter. Fisher Asset Management LLC now owns 13,118,604 shares of the company’s stock worth $1,591,811,000 after purchasing an additional 478,982 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. grew its stake in shares of Johnson & Johnson by 4.5% in the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 8,978,198 shares of the company’s stock worth $1,089,415,000 after purchasing an additional 387,504 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in shares of Johnson & Johnson by 9.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 7,552,034 shares of the company’s stock worth $967,793,000 after purchasing an additional 654,350 shares during the last quarter. 66.06% of the stock is currently owned by hedge funds and other institutional investors.

Shares of JNJ opened at $145.99 on Friday. Johnson & Johnson has a one year low of $118.62 and a one year high of $148.32. The stock has a market capitalization of $387.01 billion, a price-to-earnings ratio of 20.00, a PEG ratio of 2.26 and a beta of 0.58. The company has a quick ratio of 1.40, a current ratio of 1.72 and a debt-to-equity ratio of 0.46.



Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 16th. The company reported $2.05 EPS for the quarter, topping the consensus estimate of $2.03 by $0.02. Johnson & Johnson had a net margin of 1.89% and a return on equity of 34.62%. The company had revenue of $20.35 billion during the quarter, compared to analysts’ expectations of $20.05 billion. During the same period last year, the company posted $1.90 earnings per share. The business’s revenue for the quarter was up 3.6% on a year-over-year basis. As a group, analysts anticipate that Johnson & Johnson will post 8.16 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 11th. Investors of record on Tuesday, November 27th will be issued a dividend of $0.90 per share. This represents a $3.60 annualized dividend and a dividend yield of 2.47%. The ex-dividend date of this dividend is Monday, November 26th. Johnson & Johnson’s dividend payout ratio is currently 49.32%.

Several equities analysts have recently issued reports on JNJ shares. Credit Suisse Group lifted their price objective on shares of Johnson & Johnson from $149.00 to $152.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 17th. Citigroup raised their target price on shares of Johnson & Johnson from $137.00 to $148.00 and gave the stock a “neutral” rating in a report on Monday, October 22nd. Raymond James raised their target price on shares of Johnson & Johnson from $144.00 to $149.00 and gave the stock an “outperform” rating in a report on Wednesday, October 17th. Wells Fargo & Co reiterated an “outperform” rating and issued a $160.00 target price on shares of Johnson & Johnson in a report on Friday, September 14th. Finally, HC Wainwright reiterated a “buy” rating on shares of Johnson & Johnson in a report on Wednesday, October 17th. Two analysts have rated the stock with a sell rating, eight have given a hold rating and nine have issued a buy rating to the company. Johnson & Johnson has a consensus rating of “Hold” and an average target price of $142.54.

In related news, COO Michael E. Sneed sold 29,000 shares of the firm’s stock in a transaction that occurred on Monday, August 27th. The shares were sold at an average price of $134.80, for a total transaction of $3,909,200.00. Following the completion of the sale, the chief operating officer now directly owns 59,124 shares in the company, valued at $7,969,915.20. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CAO Ronald A. Kapusta sold 7,899 shares of the firm’s stock in a transaction that occurred on Friday, September 7th. The stock was sold at an average price of $137.18, for a total transaction of $1,083,584.82. Following the sale, the chief accounting officer now owns 25,725 shares of the company’s stock, valued at $3,528,955.50. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 349,805 shares of company stock valued at $50,593,707. 0.22% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: This article was first published by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://dakotafinancialnews.com/2018/11/18/first-trust-advisors-lp-sells-237317-shares-of-johnson-johnson-jnj.html.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Featured Article: Price to Earnings Ratio (PE)

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply